LESLIE ANNE HINDS
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner DENVER, CO NPI 1649310244
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner CO Daiichi Sankyo Inc. All categories
General Payments — all program years on this page
$6,948.80
- Category: General Payments
- Program years: PY2021–2024
- Record count: 266
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,781.13 across 74 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,552.16 | 71 |
| Education | $228.97 | 3 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Daiichi Sankyo Inc. | $199.03 | 8 |
| PFIZER INC. | $156.53 | 10 |
| Acerta Pharma LLC | $125.68 | 6 |
| AVEO Pharmaceuticals, Inc. | $124.90 | 2 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $106.13 | 5 |
| Celgene Corporation | $105.86 | 4 |
| E.R. Squibb & Sons, L.L.C. | $85.26 | 3 |
| Genmab U.S., Inc. | $81.14 | 3 |
| Gilead Sciences, Inc. | $77.51 | 4 |
| Merck Sharp & Dohme Corporation | $73.49 | 4 |
| EMD Serono, Inc. | $70.70 | 2 |
| Telix Pharmaceuticals | $67.57 | 2 |
| Astellas Pharma US Inc | $53.47 | 2 |
| Karyopharm Therapeutics Inc. | $52.38 | 2 |
| Janssen Biotech, Inc. | $44.46 | 2 |
| BOSTON SCIENTIFIC CORPORATION | $44.28 | 1 |
| GlaxoSmithKline, LLC. | $42.90 | 2 |
| Genentech USA, Inc. | $41.51 | 2 |
| GENZYME CORPORATION | $41.49 | 2 |
| SEAGEN INC. | $39.99 | 1 |
| Regeneron Healthcare Solutions, Inc. | $26.81 | 1 |
| ABBVIE INC. | $23.44 | 1 |
| Ipsen Biopharmaceuticals, Inc | $23.08 | 1 |
| Amgen Inc. | $20.20 | 1 |
| SOBI, INC | $19.82 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.41 | 1 |
| PharmaEssentia USA Corporation | $14.09 | 1 |
By program year
Records — PY2024 (74)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.